At the San Antonio Breast Cancer Symposium 2024, Dr. Paula Ines Gonzalez Ericsson presented important research on HLA class I expression in breast cancer and its implications for immunotherapy response. Her work highlights subtype-specific patterns of antigen presentation loss, providing critical insights into how checkpoint inhibitors and vaccine strategies could be optimized for different breast cancer subtypes.
By analyzing tumor-specific HLA expression, her team identified distinct molecular biases that could help tailor immunotherapeutic approaches, reinforcing the importance of personalized cancer treatment.
Thanks to Dr. Gonzalez-Ericsson and her team for their dedication to advancing breast cancer immunology and precision oncology.
Presented at: San Antonio Breast Cancer Symposium, December 10-13, 2024
Explore more about the research: https://lnkd.in/eRmXtT7F
